Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 88,372 Shares

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) major shareholder Endurance (Cayman) Ltd Svf sold 88,372 shares of the company’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $26.24, for a total transaction of $2,318,881.28. Following the sale, the insider now owns 19,699,688 shares of the company’s stock, valued at $516,919,813.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

  • On Friday, January 13th, Endurance (Cayman) Ltd Svf sold 94,199 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.54, for a total transaction of $2,500,041.46.
  • On Wednesday, January 11th, Endurance (Cayman) Ltd Svf sold 79,065 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.24, for a total transaction of $2,074,665.60.
  • On Monday, January 9th, Endurance (Cayman) Ltd Svf sold 34,801 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.85, for a total transaction of $899,605.85.
  • On Friday, January 6th, Endurance (Cayman) Ltd Svf sold 66,179 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.13, for a total transaction of $1,729,257.27.
  • On Tuesday, January 3rd, Endurance (Cayman) Ltd Svf sold 8,177 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.58, for a total transaction of $209,167.66.
  • On Tuesday, December 27th, Endurance (Cayman) Ltd Svf sold 6,850 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.59, for a total transaction of $175,291.50.
  • On Thursday, December 22nd, Endurance (Cayman) Ltd Svf sold 95,144 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.07, for a total transaction of $2,480,404.08.
  • On Tuesday, December 20th, Endurance (Cayman) Ltd Svf sold 104,026 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.53, for a total transaction of $2,655,783.78.
  • On Monday, December 5th, Endurance (Cayman) Ltd Svf sold 8,831 shares of Vir Biotechnology stock. The shares were sold at an average price of $27.25, for a total transaction of $240,644.75.
  • On Friday, December 2nd, Endurance (Cayman) Ltd Svf sold 88,462 shares of Vir Biotechnology stock. The shares were sold at an average price of $27.47, for a total transaction of $2,430,051.14.

Vir Biotechnology Stock Up 2.6 %

Shares of VIR opened at $27.59 on Friday. The stock has a market cap of $3.67 billion, a P/E ratio of 3.25 and a beta of 0.15. The business’s 50 day moving average price is $26.28 and its 200-day moving average price is $25.09. Vir Biotechnology, Inc. has a 52 week low of $18.05 and a 52 week high of $35.48.

Vir Biotechnology (NASDAQ:VIRGet Rating) last released its earnings results on Thursday, November 3rd. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $0.01 by $1.29. The company had revenue of $374.56 million during the quarter, compared to the consensus estimate of $153.79 million. On average, equities analysts anticipate that Vir Biotechnology, Inc. will post 4.61 EPS for the current year.

Institutional Investors Weigh In On Vir Biotechnology

Hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its holdings in Vir Biotechnology by 127.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $25,000 after acquiring an additional 560 shares in the last quarter. US Bancorp DE boosted its holdings in Vir Biotechnology by 175.1% in the second quarter. US Bancorp DE now owns 982 shares of the company’s stock worth $25,000 after acquiring an additional 625 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in Vir Biotechnology in the third quarter worth $25,000. SeaCrest Wealth Management LLC bought a new stake in Vir Biotechnology in the second quarter worth $36,000. Finally, Twin Lakes Capital Management LLC bought a new stake in Vir Biotechnology in the third quarter worth $42,000. 74.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Morgan Stanley upped their price objective on shares of Vir Biotechnology from $15.00 to $18.00 and gave the company an “underweight” rating in a research note on Friday, November 4th. TheStreet raised shares of Vir Biotechnology from a “d” rating to a “c-” rating in a research note on Monday, October 10th. SVB Leerink increased their price target on shares of Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Friday, November 4th. Finally, Needham & Company LLC decreased their price target on shares of Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, November 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $52.50.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.